The CLK2 (CDC-like kinase 2) antibody is a tool used to study the function and regulation of the CLK2 protein, a member of the dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) family. CLK2 plays a critical role in pre-mRNA splicing by phosphorylating serine/arginine-rich (SR) proteins, which regulate spliceosome assembly and alternative splicing. This kinase is implicated in diverse cellular processes, including cell cycle progression, stress response, and signal transduction pathways. Dysregulation of CLK2 has been linked to diseases such as cancer, neurodegenerative disorders, and metabolic syndromes, making it a potential therapeutic target.
Antibodies targeting CLK2 are essential for detecting its expression, localization, and activity in tissues or cultured cells. They enable techniques like Western blotting, immunofluorescence, and immunoprecipitation to explore CLK2's interaction partners and phosphorylation-dependent mechanisms. Research using CLK2 antibodies has revealed its role in modulating splicing factors like SRSF1 and its cross-talk with pathways such as mTOR and insulin signaling. Recent studies also highlight CLK2's involvement in cancer cell survival and response to DNA damage, suggesting its utility in biomarker discovery or drug development. Commercial CLK2 antibodies are typically validated for specificity and sensitivity across human, mouse, and rat models, supporting translational research in both basic and applied contexts.